Cognitive & Nootropic

N-Acetyl Selank Amidate

Acetylated Selank · N-Acetyl-Selank · NA-Selank Amidate

N-Acetyl Selank Amidate is a chemically modified Selank analog with N-terminal acetylation and C-terminal amidation. The caps slow peptidase breakdown versus unmodified Selank, which is why it shows up as a nasal SKU. Evidence is still the parent Selank literature - not a separate clinical program.

Not FDA-approved - research chemical

Quick answer

What it is: N-Acetyl Selank Amidate is a chemically modified Selank analog with N-terminal acetylation and C-terminal amidation.

Typical research dose: 250-750 mcg/day (intranasal)

Reconstitution calculator ↓

Research summary, not medical advice.

Reviewed by Kymata Health Editorial Team

·Last updated: August 2026·Evidence: Low

Typical research dose

250-750 mcg/day (intranasal)

Frequency

1-2× daily

Half-life

Extended vs. Selank (stable form)

Common vials

5 mg / 10 mg

CAS

N/A (modified research peptide)

Molecular weight

~800 Da (modified)

Use-case scores

0–10 against the evidence we have, not a gym ranking. Hidden domains do not apply here.

Cognition3/10
Parent Selank has Russian clinical literature. This cap/amide SKU does not. Chemistry inference is not a new trial.

Compound card

Sequence: N-acetyl Selank amide (parent is TKPRPGP)
Class: Stabilized Selank analog (no independent human PK)
Formula: N-acetyl modified Selank
Status: Not FDA-approved · research use

Dose it

5 mg + 2.5 mL BAC water → 2 mg/mL · 250 mcg ≈ 13 units (U-100)

Open in calculator

How it works

N-Acetyl Selank Amidate is the modified, stable form of Selank (a synthetic analog of the endogenous tuftsin peptide TKPR). The N-acetyl and C-terminal amide modifications substantially increase enzymatic stability and intranasal bioavailability vs. standard Selank.

Parent Selank is the molecule with the Russian clinical story. This analog is a stability edit. Do not treat vendor “stronger/longer” copy as a second trial program.

Source: Based on PMID: 18577766

Background & History

N-acetyl Selank amidate is a stabilized Selank analog. Parent Selank is the Russian tuftsin story. This SKU does not inherit a US anxiolytic NDA. NASA is the Semax twin, a different leaf.

Research Use Cases

✓Stabilized-Selank identity vs parent Selank vs NASA
✓Not a benzodiazepine replacement or psychotherapy drug

Dosing

Phase	Dose	Frequency	Notes
Intranasal Protocol	250 - 500 mcg	1-3x daily intranasal	Preferred route. Delivers directly to CNS via nasal mucosa. Effects typically felt within 15-30 minutes.
SubQ Injection	250 - 500 mcg	1-2x daily SC	For systemic dosing. Slightly longer onset than intranasal.

Administration

Route / form

Intranasal spray (preferred) or subcutaneous injection

Timing

As needed or daily. No food requirement.

Empty stomach?

No - Food timing is not critical.

N-Acetyl Selank Amidate: Nasal spray / drops vs Research vial SubQ

Nasal spray / drops

Bioavailability

Minutes-class systemic t½ is why the spray exists. Intranasal is a CNS-delivery argument, not a published US F% table for this SKU. Do not print “~100% CNS delivery” as if it were an FDA bioavailability number.

Dose note

Reconstitute the lyophilized cake, then dose the nose. Community ranges sit in the low-hundreds of mcg per day, split 1–3×. That is research-chem / CIS practice, not a US label. Do not run a BPC-style daily SubQ chart on a nasal insert.

Advantages

Matches how the Russian product and most US research SKUs are actually used.
Short plasma t½ is the reason people do not treat this like a depot GH peptide.
Selank with an acetyl cap and an amide. Not NASA (that is Semax). No analog-specific human PK.

Considerations

Sold as a nasal research SKU. Not a US NDA. This analog inherits papers from Selank. It does not have its own human PK package.
Nasal irritation is the usual complaint. Volume and osmolarity of a reconstituted cake are not a pharmacy spray.
Recon math is for making a solution. It is not a BAC SubQ lifestyle protocol.

Research vial SubQ

Bioavailability

Same cake, different hole. SubQ is community use of a nasal peptide. There is no head-to-head human PK that makes the shot “stronger.” Minutes-class parent t½ still applies.

Dose note

If the bottle is lyophilized and you inject it, BAC-reconstitute and do the unit math. Community mcg numbers are borrowed from nasal practice. Food does not change the shot. This is not a second official SKU.

Advantages

Vial math is checkable when the COA matches the sequence.
Useful only if you knowingly bought a cake and chose SubQ. It does not create a US injectable drug.

Considerations

Not the Russian labeled route. Do not invent a clinic IM ampoule because a vendor sold powder.
Systemic exposure is not a published reason to skip the nose.
Selank with an acetyl cap and an amide. Not NASA (that is Semax). No analog-specific human PK.

Recommendation: N-Acetyl Selank Amidate: nasal is the honest default. SubQ is the same research cake used as an injection, not a second approved product. Sold as a nasal research SKU. Not a US NDA. This analog inherits papers from Selank. It does not have its own human PK package. Do not flatten a spray insert into a BPC reconstitution calendar.

Timeline

Acute (15-30 min)

Anxiolytic effect. Improved focus and cognitive function. Calming without sedation.

Week 2-4 (ongoing protocol)

Reduced baseline anxiety. Improved stress resilience. Potential neuroprotective BDNF upregulation.

Who it is for

Anxiety / Stress

Low

Phase II clinical data for GAD. Non-sedating, non-addictive anxiolytic. Preferred by those seeking benzodiazepine alternatives.

Cognitive Enhancement

Low

Nootropic effects via BDNF upregulation and neurotransmitter normalization. Improved working memory and focus.

Reconstitution

Vial

5 mg

Diluent

2.5 mL

Concentration

2 mg/mL

Per Unit (100u syringe)

20 mcg

Dose of 250 mcg = 12.5 units on a 100-unit insulin syringe

Safety & Considerations

Phase II clinical data in Russia. Well-tolerated in available studies. No physical dependence or withdrawal. May cause mild nasal irritation (intranasal). Start with lower doses.

Regulatory & Legal Status

FDA Status (US)

Research Only

WADA Status (2026)

Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change - verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Limits of current evidence

Phase II GAD language belongs to parent Selank, not this analog, unless you have the analog trial.
Nasal community doses are inherited, not labeled.

Verdict

This is Selank with an acetyl cap and an amide. Vendors sell it as longer-lasting. There is no analog-specific human PK paper on this leaf. Read Selank.

Interactions & Contraindications

May theoretically add to other anxiolytics. Not a documented zero-interaction file. Intranasal vs SubQ are different products.

Synergies & Common Stacks

+ Semax →

Russian analog pair. Two research SKUs, not a psychiatry stack.

Frequently Asked Questions

Nasal or injection?▼

Nasal is how this analog is sold. Some vendor sheets also list SubQ. That is the same powder, not a new GAD trial. Parent Selank papers stay on the Selank leaf. NASA is Semax, not this peptide.

What is the difference between Selank and N-Acetyl Selank Amidate?▼

The N-acetyl and C-amide modifications dramatically improve stability and intranasal bioavailability vs. standard Selank. For intranasal delivery, N-Acetyl Selank Amidate is the preferred form due to CNS penetration and resistance to peptidase degradation.

Prescription options: compare licensed telehealth providers

Some peptide therapies are available only by prescription after a consult with a licensed clinician.

Compare telehealth →

← Back to Peptide Library